Viva Biotech buys back 1.00 million shares for HK$1.12 million; total pending cancellation climbs to 5.99 million shares

Bulletin Express06-24 18:24

Viva Biotech Holdings disclosed a fresh on-market share repurchase of 1.00 million ordinary shares on 24 June 2026, paying an average HK$1.1180 per share (high: HK$1.13; low: HK$1.11). The transaction cost the company HK$1.12 million.

The buy-back leaves Viva Biotech’s issued share capital unchanged at 2.10 billion shares as of 24 June 2026 because the repurchased shares have not yet been cancelled. Cumulatively, 5.99 million shares acquired between 8 and 24 June 2026 remain pending cancellation, equivalent to 0.28 % of the current issued share base.

Under the shareholder mandate granted on 12 June 2025, Viva Biotech is authorised to repurchase up to 212.84 million shares. To date, 31.30 million shares have been repurchased, utilising 1.47 % of the authorised limit, leaving capacity for a further 181.54 million shares.

In accordance with Hong Kong Stock Exchange rules, the company is subject to a 30-day moratorium on new share issues or treasury share sales following the latest repurchase, ending on 24 July 2026.

All repurchases have been executed in compliance with the HKEX Main Board Listing Rules, and the board has confirmed receipt of all funds related to the transactions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164010106?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164010106","market":"us","top_or_hot":-1,"title":"Viva Biotech buys back 1.00 million shares for HK$1.12 million; total pending cancellation climbs to 5.99 million shares","media":"Bulletin Express","content":"<p>Viva Biotech Holdings disclosed a fresh on-market share repurchase of 1.00 million ordinary shares on 24 June 2026, paying an average HK$1.1180 per share (high: HK$1.13; low: HK$1.11). The transaction cost the company HK$1.12 million.</p>\n<p>The buy-back leaves Viva Biotech’s issued share capital unchanged at 2.10 billion shares as of 24 June 2026 because the repurchased shares have not yet been cancelled. Cumulatively, 5.99 million shares acquired between 8 and 24 June 2026 remain pending cancellation, equivalent to 0.28 % of the current issued share base.</p>\n<p>Under the shareholder mandate granted on 12 June 2025, Viva Biotech is authorised to repurchase up to 212.84 million shares. To date, 31.30 million shares have been repurchased, utilising 1.47 % of the authorised limit, leaving capacity for a further 181.54 million shares.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, the company is subject to a 30-day moratorium on new share issues or treasury share sales following the latest repurchase, ending on 24 July 2026.</p>\n<p>All repurchases have been executed in compliance with the HKEX Main Board Listing Rules, and the board has confirmed receipt of all funds related to the transactions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech buys back 1.00 million shares for HK$1.12 million; total pending cancellation climbs to 5.99 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech buys back 1.00 million shares for HK$1.12 million; total pending cancellation climbs to 5.99 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-24 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings disclosed a fresh on-market share repurchase of 1.00 million ordinary shares on 24 June 2026, paying an average HK$1.1180 per share (high: HK$1.13; low: HK$1.11). The transaction cost the company HK$1.12 million.</p>\n<p>The buy-back leaves Viva Biotech’s issued share capital unchanged at 2.10 billion shares as of 24 June 2026 because the repurchased shares have not yet been cancelled. Cumulatively, 5.99 million shares acquired between 8 and 24 June 2026 remain pending cancellation, equivalent to 0.28 % of the current issued share base.</p>\n<p>Under the shareholder mandate granted on 12 June 2025, Viva Biotech is authorised to repurchase up to 212.84 million shares. To date, 31.30 million shares have been repurchased, utilising 1.47 % of the authorised limit, leaving capacity for a further 181.54 million shares.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, the company is subject to a 30-day moratorium on new share issues or treasury share sales following the latest repurchase, ending on 24 July 2026.</p>\n<p>All repurchases have been executed in compliance with the HKEX Main Board Listing Rules, and the board has confirmed receipt of all funds related to the transactions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1164010106","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164010106","pubTimestamp":1782296681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings disclosed a fresh on-market share repurchase of 1.00 million ordinary shares on 24 June 2026, paying an average HK$1.1180 per share (high: HK$1.13; low: HK$1.11). The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物以112万港元回购100万股；待注销总数攀升至599万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings disclosed a fresh on-market share repurchase of 1.00 million ordinary shares on 24 June 2026, paying an average HK$1.1180 per share (high: HK$1.13; low: HK$1.11). The transaction cost the company HK$1.12 million.\nThe buy-back leaves Viva Biotech’s issued share capital unchanged at 2.10 billion shares as of 24 June 2026 because the repurchased shares have not yet been cancelled. Cumulatively, 5.99 million shares acquired between 8 and 24 June 2026 remain pending cancellation, equivalent to 0.28 % of the current issued share base.\nUnder the shareholder mandate granted on 12 June 2025, Viva Biotech is authorised to repurchase up to 212.84 million shares. To date, 31.30 million shares have been repurchased, utilising 1.47 % of the authorised limit, leaving capacity for a further 181.54 million shares.\nIn accordance with Hong Kong Stock Exchange rules, the company is subject to a 30-day moratorium on new share issues or treasury share sales following the latest repurchase, ending on 24 July 2026.\nAll repurchases have been executed in compliance with the HKEX Main Board Listing Rules, and the board has confirmed receipt of all funds related to the transactions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164010106","isCrawlerRequest":true}